

TABLE OF CONTENTS

COVER PAGE.....	i
LETTER OF APPROVAL	ii
AUTHENTICITY PAGE.....	iii
PREFACE.....	iv
TABLE OF CONTENTS.....	vii
TABLE LISTS	ix
FIGURE LISTS	x
ATTACHMENT LISTS	xi
ABBREVIATIONS	xii
ABSTRACT.....	xiii
CHAPTER I. INTRODUCTION.....	1
1.1. Background.....	1
1.2. Problem Formulation.....	5
1.3. Study Objectives.....	5
1.4. Study Benefit	5
1.5. Study Authenticity	6
CHAPTER II. LITERATURE REVIEW	8
2.1. Literature Review	8
2.1.1. Thalassemia.....	8
2.1.2. Pathophysiology of thalassemia major	10
2.1.3. Clinical and laboratory diagnosis.....	11
2.1.4. Blood transfusion as the first prioritize.....	13
2.1.5. Iron overload and iron chelation	14
2.1.6. Treatment of choice for iron chelator	17
2.1.7. Clinical and laboratory evaluation of iron overload treatment	19
2.2. Basic Theory.....	20
2.3. Conceptual Framework	22
2.4. Hypothesis	22
CHAPTER III. RESEARCH METHOD	23
3.1. Study Design	23
3.2. Population and Sample	23

3.2.1. Study population	23
3.2.2. Study sample	23
3.3. Study Variable	25
3.4. Operational Definition	25
3.5. Research Instrument and Flow	26
3.6. Data Analysis	27
3.7. Study Difficulties	27
CHAPTER IV. RESULT AND DISCUSSION	28
4.1. Baseline Characteristic of Subjects	28
4.2. Difference Analysis of DFX and DFP Group in One Year	30
4.3. Difference of First and Mean of One Year SF Value in DFX and DFP Groups	31
4.4. Trend of SF Value in Each Examination and Its Mean in One Year	32
4.5. Difference of Effectiveness in Comply to Therapy Group	38
4.6. The Reason behind Uncomply Group from Questionnaires	39
4.7. Hoped Output of Study	40
4.8. Study Limitation	41
CHAPTER V. CONCLUSION AND RECOMMENDATION	42
5.1. Conclusion	42
5.2. Recommendation	43
REFERENCES	44
ATTACHMENTS	47
ETHICAL APPROVAL	55

TABLE LISTS

Table 1. Study Originality.....	7
Table 2. Guidelines for Choosing How Much Blood to Transfuse.....	14
Table 3. Information of Iron Chelator Drugs.....	18
Table 4. Operational Definition	25
Table 5. Baseline Characteristic of Subjects.....	28
Table 6. Normality Test Result for Serum Ferritin Examination.....	30
Table 7. Difference Analysis Result in DFX and DFP Group.....	31
Table 8. Difference Analysis Result of First and Mean in One Year Post Treatment DFX and DFP	32
Table 9. Difference Analysis Result of First and Mean in One Year Post Treatment in Comply Group.....	38

FIGURE LISTS

Figure 1. Theoretical Framework	21
Figure 2. Conceptual Framework	22
Figure 3. Study Flow	26
Figure 4. SF Value in Each Examinations for DFX and DFP Groups	34
Figure 5. SF Value Trend in Group with Beginning SF \leq 2500 ng/mL	36
Figure 6. SF Value Trend in Group with Beginning SF $>$ 2500 ng/mL	37
Figure 7. Result of Reason in Uncomply Group	39

ATTACHMENT LISTS

Attachment Informed Consent Form	47
Attachment Research Form.....	51
Attachment Questionnaire Form.....	53
Attachment Ethical Clearance Approval	55

ABBREVIATIONS

1. Hb : Hemoglobin (g/dL)
2. TDT : Transfusion-dependent thalassemia
3. SF : Serum ferritin (ng/mL)
4. LIC : Liver iron concentration
5. MIC : Myocardial iron concentration
6. DFO : Deferoxamine
7. DFP : Deferiprone
8. DFX : Deferasirox
9. BPJS : Badan Penyelenggara Jaminan Sosial
10. TIBC : Total iron-binding capacity
11. AHSP : α -hemoglobin stabilizing protein
12. EPO : Erythropoietin
13. MCH : Mean corpuscular hemoglobin
14. MCV : Mean corpuscular volume
15. PRC : Packed red cells
16. NTBI : Non-transferrin-bound iron
17. SQUID : Superconducting Quantum Interference Device
18. MRI : Magnetic Resonance Irradiance